Ownership Summary
A total of 9 institutions have reported a stake in Basel Medical Group Ltd (NASDAQ:BMGL) as of December 2025, according to recent 13F filings with the SEC.
- Basel Medical saw its institutional ownership percentage fell to 0.8% in December 2025 from 1.5% in September 2025.
- Quarterly data indicates a 44.55% shift in institutional share volume, and the annual owner count reflects an unavailable change.
- Of these 9 institutional investors, 7 increased their holdings in Basel Medical, while 1 of them reduced positions, and 1 investors maintained their exposure.
- The total number of shares held by institutions in Basel Medical increased to 143.02K as of December 2025, a net change of up by 44.08K shares quarter on quarter, and down N/A shares year over year.
- Ground Swell Capital, LLC's holding of 33.70K shares as of December 31, 2025 makes it the primary institutional investor in Basel Medical, owning 0.18% of the stock.
- Among the most significant buyers of Basel Medical during December 2025 were Ground Swell Capital, LLC (33.70K), XTX Topco Ltd (30.43K), JANE STREET GROUP, LLC (16.29K), SUSQUEHANNA INTERNATIONAL GROUP, LLP (15.29K), RENAISSANCE TECHNOLOGIES LLC (14.50K).
- Leading sellers of Basel Medical stock in December 2025 included CITADEL ADVISORS LLC (68.33K).
- The top 9 institutional holders of Basel Medical for the quarter ending December 2025 included Ground Swell Capital, LLC (33.70K), XTX Topco Ltd (30.43K), CITADEL ADVISORS LLC (24.67K), JANE STREET GROUP, LLC (16.29K), SUSQUEHANNA INTERNATIONAL GROUP, LLP (15.29K), RENAISSANCE TECHNOLOGIES LLC (14.50K), UBS Group AG (8.09K), Coston, McIsaac & Partners (50), CITIGROUP INC (1).